WO2002030881A1 - Sulfonylguanidine - Google Patents

Sulfonylguanidine Download PDF

Info

Publication number
WO2002030881A1
WO2002030881A1 PCT/EP2001/011245 EP0111245W WO0230881A1 WO 2002030881 A1 WO2002030881 A1 WO 2002030881A1 EP 0111245 W EP0111245 W EP 0111245W WO 0230881 A1 WO0230881 A1 WO 0230881A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methylene
ylmethyl
unsubstituted
pyridin
Prior art date
Application number
PCT/EP2001/011245
Other languages
German (de)
English (en)
French (fr)
Inventor
Matthias Gerlach
Heinz Uragg
Michael Haurand
Claudia Katharina PÜTZ
Corinna Maul
Boris Chizh
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10048716A external-priority patent/DE10048716A1/de
Priority claimed from DE10112068A external-priority patent/DE10112068A1/de
Priority to PL362349A priority Critical patent/PL207739B1/pl
Priority to AU9385201A priority patent/AU9385201A/xx
Priority to MXPA03002668A priority patent/MXPA03002668A/es
Priority to NZ525252A priority patent/NZ525252A/en
Priority to HU0303731A priority patent/HUP0303731A3/hu
Priority to CA002424107A priority patent/CA2424107A1/en
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Priority to AT01974309T priority patent/ATE509008T1/de
Priority to AU2001293852A priority patent/AU2001293852B8/en
Priority to JP2002534269A priority patent/JP4034651B2/ja
Priority to EP01974309A priority patent/EP1320520B1/de
Publication of WO2002030881A1 publication Critical patent/WO2002030881A1/de
Priority to US10/402,382 priority patent/US20030225084A1/en
Priority to US11/742,946 priority patent/US7671074B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
PCT/EP2001/011245 2000-09-30 2001-10-01 Sulfonylguanidine WO2002030881A1 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2002534269A JP4034651B2 (ja) 2000-09-30 2001-10-01 スルホニルグアニジン
EP01974309A EP1320520B1 (de) 2000-09-30 2001-10-01 Sulfonylguanidine
AT01974309T ATE509008T1 (de) 2000-09-30 2001-10-01 Sulfonylguanidine
MXPA03002668A MXPA03002668A (es) 2000-09-30 2001-10-01 Guanidinas de sulfonilo.
NZ525252A NZ525252A (en) 2000-09-30 2001-10-01 Sulfonylguanidines for use in treating pain
HU0303731A HUP0303731A3 (en) 2000-09-30 2001-10-01 Sulfonylguanidines and their use for preparation of pharmaceutical compositions
CA002424107A CA2424107A1 (en) 2000-09-30 2001-10-01 Sulfonylguanidines
PL362349A PL207739B1 (pl) 2000-09-30 2001-10-01 Sulfonyloguanidyny, ich zastosowanie oraz środki lecznicze
AU9385201A AU9385201A (en) 2000-09-30 2001-10-01 Sulfonylguanidine
AU2001293852A AU2001293852B8 (en) 2000-09-30 2001-10-01 Sulfonylguanidine
US10/402,382 US20030225084A1 (en) 2000-09-30 2003-03-31 Sulfonylguanidine compounds and pharmaceutical uses thereof
US11/742,946 US7671074B2 (en) 2000-09-30 2007-05-01 Sulfonylguanidine compounds and pharmaceutical uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10048716A DE10048716A1 (de) 2000-09-30 2000-09-30 Sulfonylguanidine
DE10048716.5 2000-09-30
DE10112068A DE10112068A1 (de) 2001-03-12 2001-03-12 Sulfonylguanidine
DE10112068.0 2001-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/402,382 Continuation US20030225084A1 (en) 2000-09-30 2003-03-31 Sulfonylguanidine compounds and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
WO2002030881A1 true WO2002030881A1 (de) 2002-04-18

Family

ID=26007237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011245 WO2002030881A1 (de) 2000-09-30 2001-10-01 Sulfonylguanidine

Country Status (13)

Country Link
US (2) US20030225084A1 (US20080085900A1-20080410-C00007.png)
EP (1) EP1320520B1 (US20080085900A1-20080410-C00007.png)
JP (1) JP4034651B2 (US20080085900A1-20080410-C00007.png)
AR (1) AR034160A1 (US20080085900A1-20080410-C00007.png)
AT (1) ATE509008T1 (US20080085900A1-20080410-C00007.png)
AU (2) AU9385201A (US20080085900A1-20080410-C00007.png)
CA (1) CA2424107A1 (US20080085900A1-20080410-C00007.png)
HU (1) HUP0303731A3 (US20080085900A1-20080410-C00007.png)
MX (1) MXPA03002668A (US20080085900A1-20080410-C00007.png)
NZ (1) NZ525252A (US20080085900A1-20080410-C00007.png)
PE (1) PE20021046A1 (US20080085900A1-20080410-C00007.png)
PL (1) PL207739B1 (US20080085900A1-20080410-C00007.png)
WO (1) WO2002030881A1 (US20080085900A1-20080410-C00007.png)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518763A (ja) * 2001-03-22 2004-06-24 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
WO2007095611A2 (en) * 2006-02-15 2007-08-23 Janssen Pharmaceutica N.V. Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2008034863A2 (en) 2006-09-22 2008-03-27 Solvay Pharmaceuticals B.V. Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
US7432299B2 (en) 2002-12-13 2008-10-07 Pfizer Inc. Method of treatment for sexual dysfunction
EP2156863A2 (en) 2003-09-12 2010-02-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
EP2196201A2 (en) 2002-12-13 2010-06-16 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
EP2366392A1 (de) * 2004-02-19 2011-09-21 Abbott GmbH & Co. KG Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195673A2 (en) * 1985-03-20 1986-09-24 Smithkline Beckman Corporation Aromatic basic-tailed vasopressin antagonists
US4900740A (en) * 1987-10-02 1990-02-13 The Nutrasweet Company N,N'-disubstituted guanidines containing a carboxyl or a tetrazolyl moiety
JPH069541A (ja) * 1992-06-19 1994-01-18 Sumitomo Pharmaceut Co Ltd α−グアニジノ酸誘導体およびその製造方法
WO1998034113A1 (en) * 1997-02-04 1998-08-06 Trega Biosciences, Inc. Combinatorial libraries of bicyclic guanidine derivatives and compounds therein
WO1999020599A1 (en) * 1997-10-21 1999-04-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
WO2000015611A1 (en) * 1998-09-14 2000-03-23 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB565566A (en) 1941-10-17 1944-11-16 American Cyanamid Co Improvements in or relating to the production of sulphonamide derivatives of nitro- and amino guanidines
DE1518852C3 (de) 1965-08-07 1974-01-24 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von N-Sulfonyl-N'-alkyl-ibzw.-arylJ-guanidinen
US4504982A (en) * 1982-08-05 1985-03-19 Optical Radiation Corporation Aspheric intraocular lens
US4904299A (en) * 1983-01-04 1990-02-27 E. I. Du Pont De Nemours And Co. Herbicidal N-hydroxy-N'-sulfonylguanidines
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US5766016A (en) * 1994-11-14 1998-06-16 Georgia Tech Research Corporation Surgical simulator and method for simulating surgical procedure
ZA977103B (en) * 1996-08-09 1999-02-08 Eisai Co Ltd Benzopiperidine derivatives
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
US6100428A (en) * 1999-10-06 2000-08-08 The University Of Kansas Nickel promoted guanylation of amines with isothioureas and thioureas
US6419359B2 (en) * 2000-04-11 2002-07-16 James Alan Edwards Surface design method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195673A2 (en) * 1985-03-20 1986-09-24 Smithkline Beckman Corporation Aromatic basic-tailed vasopressin antagonists
US4900740A (en) * 1987-10-02 1990-02-13 The Nutrasweet Company N,N'-disubstituted guanidines containing a carboxyl or a tetrazolyl moiety
JPH069541A (ja) * 1992-06-19 1994-01-18 Sumitomo Pharmaceut Co Ltd α−グアニジノ酸誘導体およびその製造方法
WO1998034113A1 (en) * 1997-02-04 1998-08-06 Trega Biosciences, Inc. Combinatorial libraries of bicyclic guanidine derivatives and compounds therein
WO1999020599A1 (en) * 1997-10-21 1999-04-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
WO2000015611A1 (en) * 1998-09-14 2000-03-23 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ANN. ACAD. MED. GEDANENSIS, vol. 22, 1992, pages 83 - 8 *
ANN. SCI. UNIV. BESANÇON, CHIM. [2], NO. 1, 16 PP. (1955) *
CHEMICAL ABSTRACTS, vol. 101, no. 11, 10 September 1984, Columbus, Ohio, US; abstract no. 90880, FISCHER, E. ET AL.: "Synthesis and properties of l.lambda4.2,4,6-thiatriazine-1-oxides. Structure of the hydrolysis product of 1-arenesulfonylimino-l.lambda4.,2,4,6-thiatriazines" XP002185319 *
CHEMICAL ABSTRACTS, vol. 115, no. 23, 9 December 1991, Columbus, Ohio, US; abstract no. 256577, EGGLESTON, IAN M. ET AL.: "The acid lability of some arginine side-chain sbstitutents related to the 2,2,5,7,8-pentamethylchroman-6-sulfonyl(Pmc) protecting group" XP002185318 *
CHEMICAL ABSTRACTS, vol. 119, no. 3, 19 July 1993, Columbus, Ohio, US; abstract no. 27802, KOZAKIEWICZ, IRENA: "Synthesis N-(2,4-dichloro-5-methylbenzenesulfonyl)-S-methylisothiourea and its use for preparation of some novel guanidine derivatives" XP002185317 *
CHEMICAL ABSTRACTS, vol. 121, no. 15, 10 October 1994, Columbus, Ohio, US; abstract no. 180208, KIMURA, YUMIKO ET AL.: "Preparation of .alpha.-guanidic acid derivatives" XP002185316 *
CHEMICAL ABSTRACTS, vol. 53, no. 21, 10 November 1959, Columbus, Ohio, US; abstract no. 21887h, ROBERT G. GALBREATH ET AL.: "Synthesis of 2-chlorophenothiazine via a Smiles rearrangement" XP002185320 *
CHEMICAL ABSTRACTS, vol. 53, no. 8, 25 April 1959, Columbus, Ohio, US; abstract no. 7062f, A. BARHON ET AL.: "N4-acylated derivatives of sulfaguanidine and of its N1'-acylated derivatives" XP002185315 *
CHEMICAL ABSTRACTS, vol. 53, no. 8, 25 April 1959, Columbus, Ohio, US; abstract no. 7062i, YU. A. BASKAKOV ET AL.: "Dervatives of hydroxy phenylamines as new herbicides" XP002185314 *
CHEMICAL ABSTRACTS, vol. 55, no. 5, 6 March 1961, Columbus, Ohio, US; abstract no. 4396e, ALFREDA DANSI ET AL.: "Reactions of N1-(.beta.-phenylethyl)biguanide" XP002185321 *
D. DUBUISSON, PAIN, vol. 4, 1977, pages 161 - 174
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002185323, Database accession no. 129:175973 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002185322, Database accession no. BRN 2899488, 2951283, 2903865 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002185324, Database accession no. BRN 4170152, 867787 *
GAZZ. CHIM. ITAL., vol. 89, 1959, pages 1681 - 6 *
J. CHEM. RES., SYNOP, no. 10, 1991, pages 286 - 7 *
J. ORG. CHEM., vol. 23, 1958, pages 1804 - 6 *
J.S. BRYANS; D.J. WUSTROW: "3-Substituted GABA Analogs with Central Nervous System Activity: A Review", MED. RES. REV., 1999, pages 149 - 177
KHIM, NAUKA I PROM., vol. 3, 1958, pages 683 - 4 *
KIM, S. H.; CHUNG, J. M.: "An experimental model for peripheral mononeuropathy produced by segmental spinal nerve ligation in the rat.", PAIN, vol. 50, 1992, pages 355 - 363
POGATZKI, E. M.; ZAHN, P. K.; BRENNAN, T. J.: "Lumbar catheterization of the subarachnoid space with a 32-gauge polyurethane catheter in the rat.", EUR. J. PAIN, vol. 4, 2000, pages 111 - 113
SUCHORUTSCHKIN ET AL., J. GEN. CHEM. USSR (ENGL. TRANSL.), vol. 34, 1964, pages 1333 *
SUGIURA ET AL., YAKUGAKU ZASSHI, vol. 90, 1970, pages 711, 714 *
T.J. CODERRE ET AL., PAIN, vol. 52, 1993, pages 259 - 285
TETRAHEDRON, vol. 40, no. 2, 1984, pages 385 - 90 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518763A (ja) * 2001-03-22 2004-06-24 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
US7432299B2 (en) 2002-12-13 2008-10-07 Pfizer Inc. Method of treatment for sexual dysfunction
EP2196201A2 (en) 2002-12-13 2010-06-16 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
EP2156863A2 (en) 2003-09-12 2010-02-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US8431604B2 (en) 2004-02-19 2013-04-30 Abbott Gmbh & Co. Kg Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
EP2366392A1 (de) * 2004-02-19 2011-09-21 Abbott GmbH & Co. KG Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007095611A3 (en) * 2006-02-15 2007-11-22 Janssen Pharmaceutica Nv Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2007095611A2 (en) * 2006-02-15 2007-08-23 Janssen Pharmaceutica N.V. Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
WO2008034863A2 (en) 2006-09-22 2008-03-27 Solvay Pharmaceuticals B.V. Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS

Also Published As

Publication number Publication date
PE20021046A1 (es) 2002-12-14
PL362349A1 (en) 2004-10-18
EP1320520A1 (de) 2003-06-25
US7671074B2 (en) 2010-03-02
CA2424107A1 (en) 2003-03-28
EP1320520B1 (de) 2011-05-11
AU9385201A (en) 2002-04-22
AR034160A1 (es) 2004-02-04
JP4034651B2 (ja) 2008-01-16
US20080085900A1 (en) 2008-04-10
AU2001293852B2 (en) 2006-11-09
JP2004511463A (ja) 2004-04-15
HUP0303731A2 (hu) 2004-03-01
US20030225084A1 (en) 2003-12-04
HUP0303731A3 (en) 2006-02-28
NZ525252A (en) 2005-12-23
MXPA03002668A (es) 2003-08-20
PL207739B1 (pl) 2011-01-31
AU2001293852B8 (en) 2006-11-30
ATE509008T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
EP0527736B1 (de) Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE60131138T2 (de) Antibakterielle mittel
US7671074B2 (en) Sulfonylguanidine compounds and pharmaceutical uses thereof
DE60131033T2 (de) Verwendungen von antikonvulsiven Aminosäure zur Behandlung bipolarer Erkrankungen
BRPI0915295A2 (pt) Derivados de n-piperidinil acetamida como bloqueadores de canal de cálcio
EP2260022B1 (de) Substituierte cyclohexyldiamine
EP1341764A1 (de) Ortho-substituierte stickstoffhaltige bisarylverbindungen zur verwendung als kalium-kanal-inhibitoren
EP1317426B1 (de) Beta-thio-aminosäuren
EP1341786B1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE10049481A1 (de) Substituierte C-Cyclohexylmethylamin-Derivate
CH678621A5 (US20080085900A1-20080410-C00007.png)
EP1326826A1 (de) Verwendung von aminosäuren zur behandlung von schmerz
DE10236910A1 (de) Substituierte 1,2,3,4-Tetrahydrochinolinderivate
DE102004023508A1 (de) Säurederivate substituierter Cyclohexyl-1,4-diamine
DE69825281T2 (de) Neue sulfonamid-derivate
DE10048716A1 (de) Sulfonylguanidine
EP1596852B1 (de) Arzneimittel enthaltend substituierte 2-heteroaryl-aminoessigsäure-verbindungen
DE10112068A1 (de) Sulfonylguanidine
EP2332529A1 (de) Substituierte aromatische Diamine als Liganden der vesikulären Glutamat-Transporter 1 und 2 (vGLUT1 und vGLUT2)
DE60108775T2 (de) Methode zur behandlung von schlaganfall
EP1596856B1 (de) Arzneimittel enthaltend substituierte 2-aryl-aminoessigsäure-verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure-verbindungen
DE19824865A1 (de) Neue Harnstoffderivate
DE10049484A1 (de) ß-Thioaminosäuren
WO2003068734A1 (de) Carbamidestern zur behandlung von schmerz
DE10206404A1 (de) Synthese von substituierten Sulfonylaminen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001974309

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002668

Country of ref document: MX

Ref document number: 2002534269

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2424107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10402382

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 525252

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001293852

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001974309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 525252

Country of ref document: NZ